[go: up one dir, main page]

AU2003265057A1 - Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy - Google Patents

Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy

Info

Publication number
AU2003265057A1
AU2003265057A1 AU2003265057A AU2003265057A AU2003265057A1 AU 2003265057 A1 AU2003265057 A1 AU 2003265057A1 AU 2003265057 A AU2003265057 A AU 2003265057A AU 2003265057 A AU2003265057 A AU 2003265057A AU 2003265057 A1 AU2003265057 A1 AU 2003265057A1
Authority
AU
Australia
Prior art keywords
vegf
idiotypic antibodies
bone therapy
fgf agonists
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003265057A
Other versions
AU2003265057A8 (en
Inventor
Karine ANDRE
Marie-Helene Lafage-Proust
Jean Plouet
Marc Trombe
Laurence VICO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABTECH
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Jean Monnet
Original Assignee
ABTECH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ABTECH filed Critical ABTECH
Publication of AU2003265057A1 publication Critical patent/AU2003265057A1/en
Publication of AU2003265057A8 publication Critical patent/AU2003265057A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003265057A 2002-09-04 2003-09-03 Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy Abandoned AU2003265057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40807602P 2002-09-04 2002-09-04
US60/408,076 2002-09-04
PCT/IB2003/004307 WO2004022095A1 (en) 2002-09-04 2003-09-03 Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy

Publications (2)

Publication Number Publication Date
AU2003265057A1 true AU2003265057A1 (en) 2004-03-29
AU2003265057A8 AU2003265057A8 (en) 2004-03-29

Family

ID=31978557

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003265057A Abandoned AU2003265057A1 (en) 2002-09-04 2003-09-03 Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy

Country Status (2)

Country Link
AU (1) AU2003265057A1 (en)
WO (1) WO2004022095A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2283666C9 (en) * 2004-05-14 2007-03-10 Бизяев Алексей Вячеславович Agent for accelerated repairing of structure and function of damaged tissues and organs
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AU2009302318A1 (en) 2008-10-10 2010-04-15 Amgen Inc. FGF21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
TWI436776B (en) 2009-05-05 2014-05-11 Amgen Inc FGF21 mutant and its use
WO2010148142A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
AU2010326024A1 (en) 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
EP4200019A1 (en) 2020-08-21 2023-06-28 Genzyme Corporation Fgfr3 antibodies and methods of use
CN112094351B (en) * 2020-09-11 2021-04-20 北京东方百泰生物科技股份有限公司 Detection antibody of anti-VEGFR-2 monoclonal antibody, application and detection method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447783B1 (en) * 1995-06-12 2002-09-10 Yeda Research And Development Co., Ltd. Compositions comprising FGF9 and use thereof for stimulating cartilage and bone repair
FR2742662B1 (en) * 1995-12-21 1998-01-23 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
FR2796073B1 (en) * 1999-07-07 2003-08-29 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES FOR FIBROBLAST GROWTH FACTORS AND THEIR USE AS MEDICAMENTS
IL139380A0 (en) * 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor

Also Published As

Publication number Publication date
WO2004022095A1 (en) 2004-03-18
AU2003265057A8 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
EP2295053B8 (en) Novel 2H-chromen-2-one-3-carboxamides for medical uses
AU2003258023A1 (en) Bone cement syringe
AU2003278393A1 (en) New use for pharmaceutical composition
AU2003243637A1 (en) Cannabinoid receptor agonists
IL164867A0 (en) Use of vegf for treating bone defects
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2003234929A1 (en) Therapeutic agent for diabetes
AU2003203378A1 (en) Suture insrument for biological use
AU2003289742A1 (en) Stable therapeutic proteins
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AU2003265057A1 (en) Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
HUP0401612A3 (en) Pharmaceutical composition suitable for treating diabetes
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003221184A1 (en) Therapeutic agent for endothelial disorder
AU2003267668A1 (en) Medical apparatus
AP2006003613A0 (en) Oral formulations for 5-HT-receptor agonists, usesand methods of treatment employing the same
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003299652A1 (en) Methods for treating diabetes
AU2003276424A1 (en) Substituted pyrido-pyridazine derivatives which enhance cognition via the gaba-a receptor
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2002309243A1 (en) Heterocyclic compounds for therapeutic use
AU2003249999A8 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
HK1074351A (en) Use of vegf for treating bone defects
AU2003227940A1 (en) Viscometers

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase